ADVERTISEMENT

Ruxolitinib receives marketing authorisation for vitiligo treatment in Europe

Deepa Varma   |   Medical News   |   24 April 2023
ADVERTISEMENT

The European Commission (EC) has granted a marketing authorisation for Opzelura (ruxolitinib) cream 15 mg/g for the treatment of nonsegmental vitiligo with facial involvement in adults and adolescents from 12 years of age. 

The approval is based on the results of two pivotal phase 3 trials ( TRuE-V1 and TRuE-V2 ...

          

September Challenge

Ends in 7d 16h
left
right

Topic Challenges

left
right